Real-World Study Evaluates Outcomes With Ipilimumab and Nivolumab in Mesothelioma

Nivolumab/Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural MesotheliomaПодробнее

Nivolumab and Ipilimumab Approved in Europe Frontline Unresectable Malignant Pleural MesotheliomaПодробнее

nIVOLUMAB & iPILIMUMAB aPPROVED IN eUROPE FOR fRONTLINE uNRESECTABLE mALIGNANT pLEURAL mESOTHELIOMAПодробнее

Real-world vs. clinical trial: efficacy of nivolumab in mRCCПодробнее

CheckMate-743 study in mesotheliomaПодробнее

NIVOLUMAB / IPILIMUMAB APPROVED IN EUROPE FOR FRONTLINE UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMAПодробнее

Real-world data for nivo in recurrent malignant pleural mesotheliomaПодробнее

FLORA: real-world second-line chemotherapy in pleural mesotheliomaПодробнее

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRCПодробнее

Real-world outcomes of brexu-cel in patients with R/R MCLПодробнее

Management of pleural mesothelioma after first line checkpoint inhibitorsПодробнее

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed...Подробнее

Managing epithelial mesotheliomaПодробнее

CheckMate 743: First-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...Подробнее

RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab in MSI/dMMR mCRCПодробнее

FDG-PET/CT vs. CT for Tumor Response to Nivolumab Plus Ipilimumab in Mesothelioma | OncotargetПодробнее

Real-world outcomes of brexu-cel in patients with R/R MCLПодробнее

FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advance...Подробнее